Relmada Therapeutics Interest Expense 2011-2026 | RLMD

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Relmada Therapeutics

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
5.15 M	2.66 M	1.2 M	1.4 M	104 K	-1.34 M	932 K	13.2 M	4.92 K	-	220 K	27.7 K	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
13.2 M	-1.34 M	2.15 M

Quarterly Interest Expense Relmada Therapeutics

2025-Q3	2025-Q2	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	1.32 M	1.36 M	1.21 M	-	828 K	387 K	330 K	-	298 K	323 K	420 K	-	363 K	404 K	408 K	-	37.9 K	-	15.9 K	-140 K	-650 K	-790 K	-652 K	29.2 K	-830	28.4 K	301 K	506 K	-24 K	506 K	-24 K	1.17 K	1.64 K	2.81 K	125	1.1 K	3.27 K	1.1 K	3.27 K	112 K	67 K	-	29.4 K	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
1.36 M	-790 K	190 K

Interest Expense of other stocks in the Drug manufacturers industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
Alimera Sciences ALIM	10.2 M	-	-	$ 142 M	USA
Adamis Pharmaceuticals Corporation ADMP	4.92 K	-	0.86 %	$ 117 M	USA
Aerie Pharmaceuticals AERI	-27.9 M	-	-	$ 754 M	USA
Canopy Growth Corporation CGC	74.6 M	$ 1.19	-	$ 128 M	Canada
AcelRx Pharmaceuticals ACRX	1.12 M	-	7.5 %	$ 6.35 M	USA
Agile Therapeutics AGRX	1.42 M	-	10.11 %	$ 58.2 M	USA
Catalent CTLT	-4 M	-	-	$ 11.5 B	USA
DURECT Corporation DRRX	2.24 M	-	-	$ 50.1 M	USA
Eagle Pharmaceuticals EGRX	4.04 M	-	-39.89 %	$ 27.7 M	USA
HEXO Corp. HEXO	20.1 M	-	2.45 %	$ 38.1 M	Canada
Endo International plc ENDP	350 M	-	-	$ 28.9 M	Irlanda
Evoke Pharma EVOK	500 K	-	-	$ 36.6 M	USA
Emergent BioSolutions EBS	87.9 M	$ 13.9	-	$ 712 M	USA
Athenex ATNX	25.8 M	-	-23.39 %	$ 1.76 M	USA
Avadel Pharmaceuticals plc AVDL	13 M	$ 21.5	-	$ 2.05 B	France
Evolus EOLS	127 K	$ 5.66	-	$ 351 M	USA
Harrow Health HROW	21.3 M	$ 51.0	-4.67 %	$ 1.66 B	USA
China Pharma Holdings CPHI	27.4 K	$ 1.35	5.88 %	$ 23.6 M	China
Sundial Growers SNDL	81 K	$ 1.65	-	$ 3.37 M	Canada
Jupiter Wellness JUPW	-5.37 M	-	-	$ 33.6 M	USA
Bausch Health Companies BHC	-28 M	$ 7.9	3.47 %	$ 2.88 B	Canada
Pacira BioSciences PCRX	-373 K	$ 26.0	-	$ 1.2 B	USA
Lannett Company LCI	58 M	-	1.15 %	$ 7.11 M	USA
Cumberland Pharmaceuticals CPIX	606 K	$ 5.19	-	$ 73 M	USA
Neoleukin Therapeutics NLTX	12 K	-	-	$ 193 M	Canada
Sonoma Pharmaceuticals SNOA	-10 K	$ 3.74	-1.58 %	$ 4.64 M	USA
Organogenesis Holdings ORGO	20 K	$ 4.3	-	$ 566 M	USA
PetIQ PETQ	38.3 M	-	1.64 %	$ 400 M	USA
Veru VERU	862 K	$ 2.37	1.72 %	$ 320 M	USA
Recro Pharma REPH	9.96 M	-	-4.76 %	$ 65.3 M	USA
Perrigo Company plc PRGO	900 K	$ 14.59	-1.19 %	$ 2 B	USA
ProPhase Labs PRPH	764 K	-	-	$ 5.07 M	USA
Rockwell Medical RMTI	2.3 M	$ 0.95	2.78 %	$ 22.2 M	USA
cbdMD YCBD	-29.5 K	$ 1.1	-	$ 4.74 M	USA
Radius Health RDUS	18.3 M	-	-	$ 1.42 B	USA
OptiNose OPTN	19.5 M	-	-	$ 1.08 B	USA
Assertio Holdings ASRT	2.78 M	$ 9.43	-1.05 %	$ 670 M	USA
Solid Biosciences SLDB	652 K	$ 5.61	-	$ 229 M	USA
SCYNEXIS SCYX	3.13 M	$ 0.64	-	$ 30.6 M	USA
Tricida TCDA	17.6 M	-	-	$ 3.25 M	USA
Tilray TLRY	46.6 M	$ 8.99	-	$ 5.56 B	Canada
TherapeuticsMD TXMD	300 K	$ 2.04	-	$ 21.3 M	USA
Viatris VTRS	592 M	$ 12.46	-	$ 15.1 B	USA
Zomedica Corp. ZOM	175 K	-	-0.21 %	$ 98 M	USA